File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: [(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?

Title[(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?
Authors
Issue Date2012
PublisherBC Decker Inc.
Citation
Molecular Imaging, 2012, v. 11 n. 3, p. 229-239 How to Cite?
Abstract
[11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p < .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects.
Persistent Identifierhttp://hdl.handle.net/10722/144590
ISSN
2013 Impact Factor: 2.191
ISI Accession Number ID

 

Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Sanatorium and Hospital
DC FieldValueLanguage
dc.contributor.authorHo, CLen_US
dc.contributor.authorCheung, MKen_US
dc.contributor.authorChen, Sen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorLeung, YLen_US
dc.contributor.authorCheng, KCen_US
dc.contributor.authorYeung, WDen_US
dc.date.accessioned2012-02-03T06:15:05Z-
dc.date.available2012-02-03T06:15:05Z-
dc.date.issued2012en_US
dc.identifier.citationMolecular Imaging, 2012, v. 11 n. 3, p. 229-239en_US
dc.identifier.issn1535-3508-
dc.identifier.urihttp://hdl.handle.net/10722/144590-
dc.description.abstract[11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p < .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects.-
dc.languageengen_US
dc.publisherBC Decker Inc.-
dc.relation.ispartofMolecular Imagingen_US
dc.subject.meshCarcinoma, Hepatocellular - pathology - radionuclide imaging-
dc.subject.meshFluorine Radioisotopes - diagnostic use - pharmacokinetics-
dc.subject.meshLiver Neoplasms - pathology - radionuclide imaging-
dc.subject.meshNeoplasm Metastasis - radionuclide imaging-
dc.subject.meshPositron-Emission Tomography and Computed Tomography - methods-
dc.title[(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?en_US
dc.typeArticleen_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2310/7290.2011.00043-
dc.identifier.pmid22554487-
dc.identifier.scopuseid_2-s2.0-84862661268-
dc.identifier.hkuros198329en_US
dc.identifier.volume11en_US
dc.identifier.issue3-
dc.identifier.spage229-
dc.identifier.epage239-
dc.identifier.isiWOS:000307646000006-
dc.publisher.placeCanada-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats